Improdia is an innovative, diagnostic company that develops clusters of novel proprietary biomarkers for monitoring the Immune Status of patients suffering from diseases associated with Chronic Inflammation. Improdia was established based on a project conceived in the Department of Immunology under Prof. Michal Baniyash at the Hebrew University of Jerusalem. ImProDia’s R&D is focusing on transferring its technology from the bench to a clinical prototype that can be successfully used in multi-central trials. The emphasis of the work revolves around product establishment and characterization, process standardization and quality control validation. The technology enables the tracking of disease regression, recurrence and treatment response, and of an individual’s immune status.